Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Press Releases
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
Real-time Euronext Amsterdam  -  05/25 11:35:02 am EDT
51.26 EUR   -0.58%
05/24Galapagos In-Licenses Drug Targets for Inflammatory Bowel Disease From Scipher
MT
05/20Intervest Offices & Warehouses Extends Lease Deals For Office Portfolio In Belgium
MT
05/09RBC Raises Price Target on Galapagos to $62 From $60, Maintains Sector Perform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société GALAPAGOS NV
05/06Galapagos creates new subscription right plans
GL
05/06Galapagos creates new subscription right plans
AQ
05/05Galapagos demonstrates regulatory and commercial progress in Q1 2022
GL
04/27GALAPAGOS : announces appointment of Dr. Paul Stoffels as Chairman of the board - Form 6-K
PU
04/26Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board
GL
04/11SUBJECT : Galapagos AGM/EGM 2022 April 11th, 2022 - Form 6-K
PU
04/11GALAPAGOS : Chairman letter to shareholders
PU
04/01GALAPAGOS : Glpg egm & agm 2022
PU
03/28Jyseleca® approved in Japan for ulcerative colitis
AQ
03/25GALAPAGOS : — Proposal of one-tier board structure & appointment of three new directo..
PU
03/24GALAPAGOS : Statutory auditor's report on the non-consolidated financial statements per 31..
PU
03/24CORRECTION : Galapagos publishes 2021 annual report and announces extraordinary and annual..
GL
03/24Galapagos publishes 2021 annual report and announces extraordinary and annual sharehold..
AQ
03/24GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
03/18Galapagos increases share capital through subscription right exercises
AQ
02/24GALAPAGOS : 2021 results set stage for future growth - Form 6-K
PU
02/24Galapagos 2021 results set stage for future growth
GL
02/07GALAPAGOS : provides further insights into the treatment of ulcerative colitis at the Euro..
PU
02/07GALAPAGOS : receives transparency notification from EcoR1 Capital - Form 6-K
PU
02/03Galapagos receives transparency notification from EcoR1 Capital
AQ
02/02Galapagos provides further insights into the treatment of ulcerative colitis at the Eur..
AQ
01/27GALAPAGOS : appoints Paul Stoffels as Chief Executive Officer - Form 6-K
PU
01/26GALAPAGOS : creates new subscription right plan - Form 6-K
PU
01/26Galapagos creates new subscription right plan
AQ
01/26Galapagos appoints Paul Stoffels as Chief Executive Officer
AQ
01/19GALAPAGOS : JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WIT..
PU
01/18Jyseleca®▼ (filgotinib) licensed for the treatment of adult patients with moderat..
AQ
01/13GALAPAGOS : creates new subscription right plan - Form 6-K
PU
01/13Galapagos creates new subscription right plan
AQ
01/10GALAPAGOS : to present at 40th Annual J.P. Morgan Healthcare Conference - Form 6-K
PU
01/06Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference
AQ
2021GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
2021Galapagos increases share capital through subscription right exercises
GL
2021Galapagos increases share capital through subscription right exercises
GL
2021GALAPAGOS : completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in poly..
PU
2021Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in pol..
AQ
2021GALAPAGOS : Jyseleca®▼(filgotinib) approved in the European Union for the treatment ..
PU
2021Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcera..
GL
2021Galapagos reports commercial and operational progress at Q3 financial results - Form 6-..
PU
2021Galapagos reports commercial and operational progress at Q3 financial results
AQ
2021GALAPAGOS : presents new data from the SELECTION Phase 3 program at the United European Ga..
PU
2021GALAPAGOS : announces completion of patient enrollment for DIVERSITY Phase 3 study with fi..
PU
2021GALAPAGOS : presents new data from the SELECTION Phase 3 program at the United European Ga..
AQ
2021GALAPAGOS : announces completion of patient enrollment for DIVERSITY Phase 3 study with fi..
AQ
2021GALAPAGOS : increases share capital through subscription right exercises (Form 6-K)
PU
2021GALAPAGOS : N.V., - Galapagos increases share capital through subscription right exercises
PU
2021GALAPAGOS : increases share capital through subscription right exercises
AQ
2021GALAPAGOS : ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT O..
PU
2021GALAPAGOS : N.v., - galapagos announces positive chmp opinion for jyseleca® (filgotinib) f..
PU
2021GALAPAGOS : Announces positive chmp opinion for jyseleca® (filgotinib) for the treatment o..
AQ
2021GALAPAGOS NV : - Bionity - Galapagos announces planned retirement of CEO
AQ
2021GALAPAGOS : announces planned retirement of CEO (Form 6-K)
PU
2021GALAPAGOS : announces planned retirement of CEO
AQ
2021GALAPAGOS : reports H1 financial results with refocused pipeline and operational progress
AQ
2021GALAPAGOS : N.V., - Galapagos reports positive topline results with selective TYK2 inhibit..
PU
2021GALAPAGOS : N.V., - Galapagos demonstrates early clinical activity with SIK2/3 inhibition ..
PU
2021GALAPAGOS : demonstrates early clinical activity with SIK2/3 inhibition in inflammation (F..
PU
2021GALAPAGOS : reports positive topline results with selective TYK2 inhibitor GLPG3667 in Pha..
PU
2021GALAPAGOS : demonstrates early clinical activity with SIK2/3 inhibition in inflammation
AQ
2021GALAPAGOS : reports positive topline results with selective TYK2 inhibitor GLPG3667 in Pha..
AQ
2021GALAPAGOS : announces new data supporting rapid symptom improvement and sustained steroid-..
AQ
2021GALAPAGOS : announces departure of CSO Piet Wigerinck later this year (Form 6-K)
PU
2021GALAPAGOS : increases share capital through subscription right exercises (Form 6-K)
PU
2021Galapagos increases share capital through subscription right exercises
GL
2021GALAPAGOS : SELECTION study on filgotinib in ulcerative colitis published in The Lancet (F..
PU
2021GALAPAGOS : to present data on rheumatoid arthritis at the upcoming European League Agains..
PU
2021GALAPAGOS : announces first patient enrolled in FILOSOPHY study to advance understanding o..
PU
2021Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding ..
GL
2021GALAPAGOS : refocuses pipeline and rightsizes operations (Form 6-K)
PU
2021GALAPAGOS : Transparency notification received from The Capital Group
AQ
2021GALAPAGOS : creates new subscription right plans
PU
2021GALAPAGOS : Written questions and answers
PU
2021GALAPAGOS : Extension of lock-up period in Gilead-Galapagos collaboration agreement
AQ
2021GALAPAGOS NV : - Publication of the annual report and invitation to the ordinary sharehold..
AQ
2021GALAPAGOS : Statutory auditor's report on the non-consolidated financial statements per 31..
PU
1  2  3  4  5  6  7Next
Official Publications
05/06Press Release 
05/051st quarter report 
05/051st quarter report 
04/26Nomination 
03/24Report 
03/24Report 
Upcoming event on GALAPAGOS NV
06/08/22Jefferies Healthcare Conference
Upcoming sector events
07/26/22IQVIA HOLDINGS INC. : Interim 2022 Earnings Release (Projected)
07/27/22LONZA GROUP AG : Interim 2022 Earnings Release (Projected)
07/28/22SEAGEN INC. : Interim 2022 Earnings Release (Projected)
08/10/22MODERNA, INC. : Interim 2022 Earnings Release (Projected)
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Other Biotechnology & Medical Research